Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Current Opinion in Nephrology and Hypertension|June 2, 2021
Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney diseaseMohanad Almaimani, Vikas S Sridhar, David Z I Cherney
Transplantation|April 2, 2021
Cancer Screening in Solid Organ Transplant Recipients: A Focus on Screening Liver, Lung, and Kidney Recipients for Cancers Related to the Transplanted OrganAtit Dharia, Jacinthe Boulet, Vikas S Sridhar, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 30, 2023
Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia: A Review of the Evidence From Clinical TrialsRehab B Albakr, Vikas S Sridhar, David Z I Cherney
Jornal Brasileiro De Nefrologia|September 14, 2020
Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protectionVikas S Sridhar, Lisa Dubrofsky, Jacinthe Boulet, et al.
Diabetes, Obesity & Metabolism|April 9, 2020
What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?Vikas S Sridhar, Habib U Rahman, David Z I Cherney
Annual Review of Medicine|January 27, 2023
SGLT2 Inhibitors: The Sweet Success for KidneysAtit Dharia, Abid Khan, Vikas S Sridhar, et al.
Nature Reviews. Nephrology|January 12, 2026
Next-generation therapeutics for diabetic kidney diseaseTae Won Yi, Vikas S Sridhar, Jennifer Scott, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|March 28, 2024
Inflammation in heart failure: pathophysiology and therapeutic strategiesJacinthe Boulet, Vikas S Sridhar, Nadia Bouabdallaoui, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 1, 2024
Proximal versus distal diuretics in congestive heart failureMassimo Nardone, Vikas S Sridhar, Kevin Yau, et al.
Current Diabetes Reports|May 28, 2022
SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic KetoacidosisHongyan Liu, Vikas S Sridhar, Bruce A Perkins, et al.
Pageof 5